SIRPA and neoplasm: AO-176 not only blocked CD47/SIRP-α interaction to induce phagocytosis of tumor cells by macrophages but also directly induced dose-dependent anti-tumor activity in murine xenograft models of lymphoma, breast cancer, ovarian cancer, and gastric cancer; furthermore, AO-176 exhibited low affinity to red blood cells and favorable tolerability in cynomolgus monkeys, rendering it a promising drug candidate (149).